Application of target-mediated drug disposition model to small molecule heat shock protein 90 inhibitors

Drug Metabolism and Disposition

Volumn 41, Issue 6, 2013, Pages 1285-1294

  Yamazaki, Shinji ^a   Shen, Zhongzhou ^a,b   Jiang, Ying ^a   Smith, Bill J ^a   Vicini, Paolo ^a  

^a PFIZER INC   (United States)

^b DART NEUROSCIENCE LLC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEAT SHOCK PROTEIN 90 INHIBITOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DISPOSITION; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG PROTEIN BINDING; DRUG STRUCTURE; DRUG URINE LEVEL; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IN VITRO STUDY; IN VIVO STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; METABOLIC CLEARANCE RATE; NONHUMAN; PRIORITY JOURNAL; RAT; TARGET MEDIATED DRUG DISPOSITION; TIME TO MAXIMUM PLASMA CONCENTRATION; TISSUE DISTRIBUTION;

ANIMALS; DRUG DELIVERY SYSTEMS; HSP90 HEAT-SHOCK PROTEINS; MALE; MICROSOMES, LIVER; PHARMACEUTICAL PREPARATIONS; PROTEIN BINDING; RATS; RATS, SPRAGUE-DAWLEY; TISSUE DISTRIBUTION;

EID: 84878215338     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.113.051490     Document Type: Article

References (34)

1. Caldas-Lopes E, Cerchietti L, Ahn JH, Clement CC, Robles AI, Rodina A, Moulick K, Taldone T, Gozman A, and Guo Y, et al. (2009) Hsp90 inhibitor PU-H71, a multimodal inhibitor of malignancy, induces complete responses in triple-negative breast cancer models. Proc Natl Acad Sci USA 106:8368-8373.
2. Csermely P, Schnaider T, Soti C, Prohászka Z, and Nardai G (1998) The 90-kDa molecular chaperone family: structure, function, and clinical applications. A comprehensive review. Pharmacol Ther 79:129-168.
3. Di L, Whitney-Pickett C, Umland JP, Zhang H, Zhang X, Gebhard DF, Lai Y, Federico JJ, 3rd, Davidson RE, and Smith R, et al. (2011) Development of a new permeability assay using lowefflux MDCKII cells. J Pharm Sci 100:4974-4985.
4. Eiseman JL, Lan J, Lagattuta TF, Hamburger DR, Joseph E, Covey JM, and Egorin MJ (2005) Pharmacokinetics and pharmacodynamics of 17-demethoxy 17-[[(2-dimethylamino) ethyl] amino]geldanamycin (17DMAG, NSC 707545) in C. B-17 SCID mice bearing MDA-MB-231 human breast cancer xenografts. Cancer Chemother Pharmacol 55:21-32.
5. Gibiansky L and Gibiansky E (2009) Target-mediated drug disposition model: approximations, identifiability of model parameters and applications to the population pharmacokineticpharmacodynamic modeling of biologics. Expert Opin Drug Metab Toxicol 5:803-812.
6. Goetz MP, Toft DO, Ames MM, and Erlichman C (2003) The Hsp90 chaperone complex as a novel target for cancer therapy. Ann Oncol 14:1169-1176.
7. Holzbeierlein JM, Windsperger A, and Vielhauer G (2010) Hsp90: a drug target? Curr Oncol Rep 12:95-101.
8. Jensen MR, Schoepfer J, Radimerski T, Massey A, Guy CT, Brueggen J, Quadt C, Buckler A, Cozens R, and Drysdale MJ, et al. (2008) NVP-AUY922: a small molecule HSP90 inhibitor with potent antitumor activity in preclinical breast cancer models. Breast Cancer Res 10:R33.
9. Kung PP, Huang B, Zhang G, Zhou JZ, Wang J, Digits JA, Skaptason J, Yamazaki S, Neul D, and Zientek M, et al. (2010) Dihydroxyphenylisoindoline amides as orally bioavailable inhibitors of the heat shock protein 90 (hsp90) molecular chaperone. J Med Chem 53:499-503.
10. Levy G (1994) Pharmacologic target-mediated drug disposition. Clin Pharmacol Ther 56:248-252.
11. Li Y, Zhang T, Schwartz SJ, and Sun D (2009) New developments in Hsp90 inhibitors as anti-cancer therapeutics: mechanisms, clinical perspective and more potential. Drug Resist Updat 12:17-27.
12. Mager DE (2006) Target-mediated drug disposition and dynamics. Biochem Pharmacol 72:1-10.
13. Mager DE and Jusko WJ (2001) General pharmacokinetic model for drugs exhibiting targetmediated drug disposition. J Pharmacokinet Pharmacodyn 28:507-532.
14. Mager DE and Krzyzanski W (2005) Quasi-equilibrium pharmacokinetic model for drugs exhibiting target-mediated drug disposition. Pharm Res 22:1589-1596.
15. Mager DE, Mascelli MA, Kleiman NS, Fitzgerald DJ, and Abernethy DR (2003) Simultaneous modeling of abciximab plasma concentrations and ex vivo pharmacodynamics in patients undergoing coronary angioplasty. J Pharmacol Exp Ther 307:969-976.
16. Mahalingam D, Swords R, Carew JS, Nawrocki ST, Bhalla K, and Giles FJ (2009) Targeting HSP90 for cancer therapy. Br J Cancer 100:1523-1529.
17. Marathe A, Krzyzanski W, and Mager DE (2009) Numerical validation and properties of a rapid binding approximation of a target-mediated drug disposition pharmacokinetic model. J Pharmacokinet Pharmacodyn 36:199-219.
18. Mehta PP, Whalen P, Baxi SM, Kung PP, Yamazaki S, and Yin MJ (2011) Effective targeting of triple-negative breast cancer cells by PF-4942847, a novel oral inhibitor of Hsp 90. Clin Cancer Res 17:5432-5442.
19. Pacey S, Wilson RH, Walton M, Eatock MM, Hardcastle A, Zetterlund A, Arkenau HT, Moreno-Farre J, Banerji U, and Roels B, et al. (2011) A phase I study of the heat shock protein 90 inhibitor alvespimycin (17-DMAG) given intravenously to patients with advanced solid tumors. Clin Cancer Res 17:1561-1570.
20. Parsell DA and Lindquist S (1993) The function of heat-shock proteins in stress tolerance: degradation and reactivation of damaged proteins. Annu Rev Genet 27:437-496.
21. Rajan A, Kelly RJ, Trepel JB, Kim YS, Alarcon SV, Kummar S, Gutierrez M, Crandon S, Zein WM, and Jain L, et al. (2011) A phase I study of PF-04929113 (SNX-5422), an orally bioavailable heat shock protein 90 inhibitor, in patients with refractory solid tumor malignancies and lymphomas. Clin Cancer Res 17:6831-6839.
22. Rodgers T, Leahy D, and Rowland M (2005) Physiologically based pharmacokinetic modeling 1: predicting the tissue distribution of moderate-to-strong bases. J Pharm Sci 94:1259-1276.
23. Trepel J, Mollapour M, Giaccone G, and Neckers L (2010) Targeting the dynamic HSP90 complex in cancer. Nat Rev Cancer 10:537-549.
24. Wagner JG (1971) A new generalized nonlinear pharmacokinetic model and its implications, Drug Intelligence Publications, Hamilton, IL.
25. Wählby U, Jonsson EN, and Karlsson MO (2001) Assessment of actual significance levels for covariate effects in NONMEM. J Pharmacokinet Pharmacodyn 28:231-252.
26. Wayne N, Mishra P, and Bolon DN (2011) Hsp90 and client protein maturation. Methods Mol Biol 787:33-44.
27. Whitesell L and Lindquist SL (2005) HSP90 and the chaperoning of cancer. Nat Rev Cancer 5:761-772.
28. Woo S, Krzyzanski W, and Jusko WJ (2007) Target-mediated pharmacokinetic and pharmacodynamic model of recombinant human erythropoietin (rHuEPO). J Pharmacokinet Pharmacodyn 34:849-868.
29. Woodhead AJ, Angove H, Carr MG, Chessari G, Congreve M, Coyle JE, Cosme J, Graham B, Day PJ, and Downham R, et al. (2010) Discovery of (2, 4-dihydroxy-5-isopropylphenyl)-[5-(4-methylpiperazin-1-ylmethyl)-1, 3-dihydroisoindol-2-yl]methanone (AT13387), a novel inhibitor of the molecular chaperone Hsp90 by fragment based drug design. J Med Chem 53:5956-5969.
30. Yamazaki S, Skaptason J, Romero D, Lee JH, Zou HY, Christensen JG, Koup JR, Smith BJ, and Koudriakova T (2008) Pharmacokinetic-pharmacodynamic modeling of biomarker response and tumor growth inhibition to an orally available cMet kinase inhibitor in human tumor xenograft mouse models. Drug Metab Dispos 36:1267-1274.
31. Yamazaki S, Nguyen L, Vekich S, Shen Z, Yin MJ, Mehta PP, Kung PP, and Vicini P (2011a) Pharmacokinetic-pharmacodynamic modeling of biomarker response and tumor growth inhibition to an orally available heat shock protein 90 inhibitor in a human tumor xenograft mouse model. J Pharmacol Exp Ther 338:964-973.
32. Yamazaki S, Skaptason J, Romero D, Vekich S, Jones HM, Tan W, Wilner KD, and Koudriakova T (2011b) Prediction of oral pharmacokinetics of cMet kinase inhibitors in humans: physiologically based pharmacokinetic model versus traditional one-compartment model. Drug Metab Dispos 39:383-393.
33. Zehnder L, Bennett M, Meng J, Huang B, Ninkovic S, Wang F, Braganza J, Tatlock J, Jewell T, and Zhou JZ, et al. (2011) Optimization of potent, selective, and orally bioavailable pyrrolodinopyrimidine-containing inhibitors of heat shock protein 90. Identification of development candidate 2-amino-4-4-chloro-2-[2-(4-fluoro-1H-pyrazol-1-yl) ethoxy]-6-methylphenyl-N-(2, 2-difluoropropyl)-5, 7-dihydro-6H-pyrrolo[3, 4-d]pyrimidine-6-carboxamide. J Med Chem 54:3368-3385.
34. Zhu H, Woolfenden S, Bronson RT, Jaffer ZM, Barluenga S, Winssinger N, Rubenstein AE, Chen R, and Charest A (2010) The novel Hsp90 inhibitor NXD30001 induces tumor regression in a genetically engineered mouse model of glioblastoma multiforme. Mol Cancer Ther 9:2618-2626.